Bristol-Myers Squibb stock heads into the open after a 3.2 percent drop
Published on 09/10/2026 at 03:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb stock closed at USD 64.69 on the NYSE on September 9, 2026, down 3.19 percent from the prior session according to NYSE data cited by MarketWatch. The shares moved in a day range between USD 64.40 and USD 65.89, while the 52-week range stood between USD 42.52 and USD 68.64, showing the latest close near the upper third of the past year per MarketWatch data. The broader U.S. market also weakened, with the Dow Jones Industrial Average falling 1.2 percent to 52,786.07 on September 9, 2026, underscoring that the stock followed a wider equity pullback.
September 9, 2026 in numbers
Bristol-Myers Squibb Co. (ISIN US1078421011, NYSE: BMY) faced selling pressure in the last completed session as it slipped to a USD 64.69 close on the NYSE on September 9, 2026, marking a 3.19 percent decline versus the previous day based on MarketWatch quote data. That closing price remained within the intraday span from USD 64.40 to USD 65.89 and comfortably inside the documented 52-week corridor of USD 42.52 to USD 68.64 per MarketWatch data. Trading took place against a weak macro backdrop, with the Dow Jones Industrial Average losing 1.2 percent to finish at 52,786.07 on September 9, 2026, as reported by Yahoo Finance, so Bristol-Myers Squibb broadly tracked the risk-off tone in U.S. equities rather than diverging sharply from the index move.
Today's catalysts for Bristol-Myers Squibb
Company-specific earnings or major corporate events for Bristol-Myers Squibb on September 10, 2026 are not highlighted in the latest public filings or news reports, with recent attention instead focused on previously released quarterly results detailing revenue trends, as noted by StockTitan. Into today's session, investors may therefore react primarily to the broader market backdrop, including the prior day's decline in major U.S. indices and any fresh macroeconomic headlines that could influence healthcare valuations, while Bristol-Myers Squibb enters the pre-market with its share price still relatively close to the upper segment of its documented 52-week range.
